2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3208 AML-associated RUNX1 mutations have distinct protein interactomes that may be relevant to AML pathogenesis

Thu Huynh, BS, Caden Perry, BA2, Sai Mukund Ramakrishnan, MS3, Christopher A. Miller, PhD4, Ryan B. Day, MD, PhD5
1 Washington University in St. Louis, Saint Louis, Missouri, United States
2 Washington University in St. Louis, Saint Louis, Missouri, United States
3 Washington University in St. Louis, Saint Louis, Missouri, United States
4 Washington University in St. Louis, Saint Louis, Missouri, United States
5 Washington University in St. Louis, Saint Louis, Missouri, United States

RUNX1 is one of the most commonly mutated genes in acute myeloid leukemia (AML), and is associated with high rates of chemorefractory disease and poor outcomes. The mechanisms by which RUNX1 mutations contribute to AML pathogenesis remain poorly understood, and no therapies exist to target mutant RUNX1 in AML. To better understand how RUNX1 influences AML pathogenesis, we used the TurboID proximity ligase system to characterize the protein interactome of RUNX1 in murine hematopoietic stem and progenitor cells. We initially defined the protein interactomes of the main RUNX1 isoforms in hematopoietic cells: the long RUNX1C isoform, which contains the Runt homology domain that binds DNA and the transactivation domain (TAD) that interacts with transcriptional machinery to drive gene transcription, and the short RUNX1A isoform, which lacks the TAD and is thought to function as a loss-of-function or dominant negative isoform, and has been reported to be upregulated in AML. As expected, the long RUNX1C isoform predominantly interacted with nuclear proteins involved in gene transcription and chromatin regulation. While the short RUNX1A isoform lost protein interactions with transcriptional regulators (as predicted based on the absence of the TAD), it gained novel interactions with a variety of proteins. Gene ontology analysis revealed enrichment for proteins involved in mitosis and sister chromatid organization, and protein domain analysis showed significant enrichment for ARM and PWWP domain-containing proteins, including DNMT3A. These data suggest that the short isoform is not a simple loss-of-function isoform—it instead has a novel protein interactome that may be functionally relevant. To determine whether these novel interactions were due to unique RUNX1A protein sequences, or inhibited by the absence of the long RUNX1C C-terminus, we performed TurboID using a long RUNX1C isoform variant truncated at exon 7, the last shared exon between the two isoforms. This isoform mimicked the short RUNX1A isoform protein interactome, demonstrating that the absence of the long isoform C-terminus is sufficient to reproduce the short isoform TurboID interactome. Interestingly, many AML-associated RUNX1 mutations mimic the short isoform by prematurely truncating RUNX1 protein. To determine whether AML-associated RUNX1 mutations alter the RUNX1 protein interactome, we performed TurboID using the AML-associated RUNX1 mutations RUNX1R201*, RUNX1R204Q, and RUNX1W279*, and compared their protein interactomes to that of full-length RUNX1C. RUNX1W279* most closely approximated the short isoform protein interactome, losing interactions with proteins associated with gene transcription, and gaining interactions with multiple PWWP and ARM-domain containing proteins. RUNX1R201* had a strikingly distinct interactome. While full-length RUNX1C primarily interacted with proteins predicted to have a nuclear localization, RUNX1R201* primarily interacted with proteins predicted to have a cytoplasmic localization, suggesting that RUNX1R201* may be mislocalized to the cytoplasm. Finally, RUNX1R204Q maintained its interaction with many transcriptional proteins, consistent with the presence of the full-length TAD, but gained interactions with proteins involved in RNA processing like PABPC1 and SRSF4, suggesting a novel role in RNA metabolism. Ongoing studies are focused on extending these results to other RUNX1 mutations and determining how RUNX1 mutations affect subcellular localization of RUNX1 protein. Overall, these data strongly suggest that AML-associated RUNX1 mutations have unexpected and unique protein interactomes and interacting pathways, which may represent potential therapeutic targets to inhibit mutant RUNX1 function, while leaving wildtype function intact.

Ryan B. Day, MD, PhD: No relevant conflicts of interest to declare.